KAIROS THERAPEUTICS
Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform.
KAIROS THERAPEUTICS
Industry:
Biotechnology Life Science Medical
Founded:
2013-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.kairostherapeutics.com
Total Employee:
51+
Status:
Closed
Contact:
(206) 237-1030
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Amazon Microsoft Azure DNS DNS Made Easy DNS
Investors List
Accel-Rx Health Sciences Accelerator
Accel-Rx Health Sciences Accelerator investment in Pre Seed Round - Kairos Therapeutics
Official Site Inspections
http://www.kairostherapeutics.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Kairos Therapeutics"
Cutting-edge therapeutics for cancer patients | Kairos …
Kairos Pharma is a clinical-stage biopharmaceutical company that has developed novel therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression.See details»
Kairos Therapeutics Company Profile 2024: Valuation, …
Kairos Therapeutics General Information Description. Developer of antibody-drug conjugate therapeutics for cancer. The company provides an antibody-drug conjugate platform that enables development of therapeutics for the treatment …See details»
Kairos Therapeutics Inc - Company Profile and News
Company profile page for Kairos Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Kairos Pharma, Ltd. - Investor Relations
Oct 9, 2024 Company Overview. Kairos Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies designed to overcome drug resistance and …See details»
Kairos Therapeutics | Scientist.com
Kairos Therapeutics is developing a pipeline of antibody-drug conjugate (ADC) therapeutics for the treatment of various forms of cancer. The technology was developed in-house at The …See details»
Kairos Therapeutics - Products, Competitors, Financials, Employees ...
Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform based on novel toxin, linker, and site-specific conjugation technology. …See details»
Zymeworks and Kairos Therapeutics Enter into Strategic …
Jan 8, 2016 Kairos Therapeutics is developing a pipeline of antibody-drug conjugate therapeutics based on a proprietary toxin, linker and site-specific conjugation platform. The …See details»
Kairos Therapeutics - Funding, Financials, Valuation & Investors
Jan 1, 2015 Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform. Search Crunchbase. Start Free Trial . ... How …See details»
Zymeworks Completes Acquisition of Kairos Therapeutics
Mar 22, 2016 Zymeworks Inc. announced that it has completed the merger and acquisition of Kairos Therapeutics, specialists in the discovery and development of antibody drugconjugates (ADCs), spun out of The Centre for Drug …See details»
Pipeline | Kairos Pharma
2013+ June 2013 - Spun-off from Cedars-Sinai Medical Center; June 2014 - Raised $525k from Founders / Pennsylvania Biotechnology Grant; July 2016 - Name changed to Kairos Pharma and licensed immunotherapy technology …See details»
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug ...
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug ...See details»
Kairos goes public with $6M IPO to fund trials of cancer drug
Sep 17, 2024 Behind ENV 105 are preclinical candidates like KROS 101, a small molecule agonist for the GITR ligand, which is designed to promote T cell growth and cytotoxic function …See details»
Kairos Therapeutic Retreat (@kairostherapeutics) - Instagram
Kairostherapeutics. Follow. Message. 32 posts. 122 followers. 134 following. Kairos Therapeutic Retreat. Nonprofit organization. Providing a sanctuary of healing and an ecosystem for …See details»
Kairos Pharma Doses First Patients in Phase 1 Trial of Lead
LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to...See details»
Kairos gets FDA clearance to begin Phase I trial of glioblastoma …
Mar 15, 2022 Kairos noted that these cells have demonstrated to destroy cancer stem cells, which are the key root cause of cancer. Sponsored by Kairos Pharma, the Phase I trial of …See details»
Kairos Pharma Announces FDA Clearance of Investigational New …
LOS ANGELES, Feb. 15, 2022 /PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for …See details»
Zymeworks and Kairos Therapeutics Enter into Strategic …
Jan 8, 2016 Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, today announced they have entered into a strategic …See details»
Kairos Pharma Receives FDA Approval of Investigational New Drug …
Mar 14, 2022 Phase 1 clinical trial of KROS 201 to begin in 2022 at Cedars Sinai Medical Center. New patent covers the method of treating fibrosis and certain forms of cancer, the …See details»
Kairos Therapeutics Inc.: Armed Malaria Protein Found to Kill …
Oct 13, 2015 Kairos Therapeutics, a Vancouver-based biotech company spun-out of The Centre for Drug Research and Development (CDRD), has partnered with VAR2 Pharmaceuticals to …See details»